Reimbursement decision provides eligible Ontarians living with generalized myasthenia gravis with an additional treatment option that may offer greater flexibility, independence, and individualized care.

^PrRYSTIGGO® (rozanolixizumab injection) and ^PrZILBRYSQ® (zilucoplan injection) are now publicly reimbursed in multiple provinces in Canada, as well as through Veterans Affairs Canada and the Non-Insured Health Benefits Program.

Following an examination of clinical evidence and stakeholder input, Canada’s Drug Agency (CDA-AMC) has recommendedBIMZELX® (bimekizumab injection) for reimbursement with conditions for patients with moderate to severe hidradenitis suppurativa. 

UCB, a global biopharmaceutical company committed to improving the lives of people with severe diseases, announced the expansion of its FASTRAX Canada program into Québec City.

Receives Positive Reimbursement Recommendation from INESSS for Adults Living with Moderate to Severe Hidradenitis Suppurativa (HS)

UCB Canada remains dedicated to helping patients and working collaboratively with CDA-AMC following draft recommendation for ^PrBIMZELX^® for hidradenitis suppurativa (HS)